11-14 June, 2022
ATLANTA, GEORGIA
ENDO 2022 Medfyle Meeting Coverage
Welcome to ENDO 2022 Medfyle Meeting Coverage.
In this program, we offer you a range of conferences summaries, interviews, and poster podcasts from presentations held at ENDO 2022.
ENDO is the foremost meeting in endocrinology, welcoming leading experts, researchers, and the most respected clinicians to share the latest developments in endocrine research.
If you have any comments or need any help, please complete our feedback survey or contact us.
Deep dive on Incretin Therapy
Deep Dive on incretin therapy
60
Introduction: Incretin Hormones and Glucagon
1408
Dual Incretin Receptor Agonists and Glycemic Control
1765
Cardiovascular Benefits of Dual Incretin Agonists
1839
Dual Incretin Receptor Agonists and body weight
Glucagon action: New twists for an old peptide
16
What potential advantages might triple incretin agonists have over dual agonists?
66
What new aspects have been understood with regards to the action of glucagon and how is this peptide being exploited from a therapeutic standpoint?
120
What role does GIP have in obesity?
181
Where might dual incretin agonists be placed in the therapeutic algorithm for type 2 diabetes?
Deep dive on Advances in Insulin Technology
Deep Dive on Advances in Insulin and Its Delivery
73
Weekly Basal Insulins
350
Insulin-Only Bionic Pancreas Pivotal Trial
785
Insulin-Only Bioninc Pancreas Pivotal Trial Lispro/Aspart vs Fast Acting Insulin Aspart
846
Insulin Access in the USA
Is the Pen Mightier than the Pump? Integration of Smart Pens in Clinical Practice.
16
What are some of the advantages of insulin pumps over pens, and vice versa?
83
What do patients consider most when deciding to adopt an insulin pen or pump?
161
Do insulin pumps allow for better control of glycemia?
222
Which patients would be most appropriate for insulin pumps or pens?
THIS ACTIVITY IS SUPPORTED BY AN EDUCATIONAL GRANT FROM LILLY
